Free Trial
→ Why this tiny stock may move before the SpaceX IPO drops (From Behind the Markets) (Ad)tc pixel Free CALA Stock Alerts

Calithera Biosciences (CALA) Competitors

Calithera Biosciences logo
$0.0003 0.00 (0.00%)
As of 06/12/2026
Compare

CALA vs. CARM, CMRA, EVLO, EFTR, and STAB

Should you buy Calithera Biosciences stock or one of its competitors? MarketBeat compares Calithera Biosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Calithera Biosciences include Carisma Therapeutics (CARM), Comera Life Sciences (CMRA), Evelo Biosciences (EVLO), eFFECTOR Therapeutics (EFTR), and Statera Biopharma (STAB). These companies are all part of the "pharmaceutical products" industry.

How does Calithera Biosciences compare to Carisma Therapeutics?

Carisma Therapeutics (NASDAQ:CARM) and Calithera Biosciences (NASDAQ:CALA) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, earnings, valuation, profitability, media sentiment and dividends.

In the previous week, Carisma Therapeutics' average media sentiment score of 0.00 equaled Calithera Biosciences'average media sentiment score.

Company Overall Sentiment
Carisma Therapeutics Neutral
Calithera Biosciences Neutral

Calithera Biosciences has a net margin of 0.00% compared to Carisma Therapeutics' net margin of -254.28%.

Company Net Margins Return on Equity Return on Assets
Carisma Therapeutics-254.28% N/A -192.17%
Calithera Biosciences N/A N/A N/A

44.3% of Carisma Therapeutics shares are owned by institutional investors. 6.9% of Carisma Therapeutics shares are owned by insiders. Comparatively, 6.6% of Calithera Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Carisma Therapeutics presently has a consensus price target of $1.00, indicating a potential upside of 19,507.84%. Given Carisma Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Carisma Therapeutics is more favorable than Calithera Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Carisma Therapeutics
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
2.67
Calithera Biosciences
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Calithera Biosciences has lower revenue, but higher earnings than Carisma Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Carisma Therapeutics$10.77M0.02-$60.48M$0.730.01
Calithera BiosciencesN/AN/A-$39.65MN/AN/A

Carisma Therapeutics has a beta of 0.79, meaning that its stock price is 21% less volatile than the broader market. Comparatively, Calithera Biosciences has a beta of -1.32, meaning that its stock price is 232% less volatile than the broader market.

Summary

Carisma Therapeutics beats Calithera Biosciences on 9 of the 12 factors compared between the two stocks.

How does Calithera Biosciences compare to Comera Life Sciences?

Comera Life Sciences (NASDAQ:CMRA) and Calithera Biosciences (NASDAQ:CALA) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, valuation, earnings, dividends, institutional ownership, risk, media sentiment and analyst recommendations.

Comera Life Sciences has a beta of 1.07, indicating that its stock price is 7% more volatile than the broader market. Comparatively, Calithera Biosciences has a beta of -1.32, indicating that its stock price is 232% less volatile than the broader market.

In the previous week, Comera Life Sciences' average media sentiment score of 0.00 equaled Calithera Biosciences'average media sentiment score.

Company Overall Sentiment
Comera Life Sciences Neutral
Calithera Biosciences Neutral

Company Net Margins Return on Equity Return on Assets
Comera Life SciencesN/A N/A N/A
Calithera Biosciences N/A N/A N/A

Comera Life Sciences has higher revenue and earnings than Calithera Biosciences.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Comera Life Sciences$1.00M0.00-$18M-$0.31N/A
Calithera BiosciencesN/AN/A-$39.65MN/AN/A

Summary

Comera Life Sciences beats Calithera Biosciences on 3 of the 4 factors compared between the two stocks.

How does Calithera Biosciences compare to Evelo Biosciences?

Evelo Biosciences (NASDAQ:EVLO) and Calithera Biosciences (NASDAQ:CALA) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, media sentiment, dividends, risk, profitability, valuation and earnings.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Evelo BiosciencesN/AN/A-$114.53M-$8.81N/A
Calithera BiosciencesN/AN/A-$39.65MN/AN/A

Evelo Biosciences has a beta of 1.78, suggesting that its share price is 78% more volatile than the broader market. Comparatively, Calithera Biosciences has a beta of -1.32, suggesting that its share price is 232% less volatile than the broader market.

In the previous week, Evelo Biosciences' average media sentiment score of 0.00 equaled Calithera Biosciences'average media sentiment score.

Company Overall Sentiment
Evelo Biosciences Neutral
Calithera Biosciences Neutral

Company Net Margins Return on Equity Return on Assets
Evelo BiosciencesN/A N/A N/A
Calithera Biosciences N/A N/A N/A

0.3% of Evelo Biosciences shares are owned by institutional investors. 1.0% of Evelo Biosciences shares are owned by company insiders. Comparatively, 6.6% of Calithera Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Evelo Biosciences beats Calithera Biosciences on 3 of the 5 factors compared between the two stocks.

How does Calithera Biosciences compare to eFFECTOR Therapeutics?

Calithera Biosciences (NASDAQ:CALA) and eFFECTOR Therapeutics (NASDAQ:EFTR) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, profitability, earnings, valuation and media sentiment.

Calithera Biosciences has a beta of -1.32, suggesting that its stock price is 232% less volatile than the broader market. Comparatively, eFFECTOR Therapeutics has a beta of 2.4, suggesting that its stock price is 140% more volatile than the broader market.

In the previous week, Calithera Biosciences' average media sentiment score of 0.00 equaled eFFECTOR Therapeutics'average media sentiment score.

Company Overall Sentiment
Calithera Biosciences Neutral
eFFECTOR Therapeutics Neutral

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Calithera BiosciencesN/AN/A-$39.65MN/AN/A
eFFECTOR TherapeuticsN/AN/A-$35.81M-$13.08N/A

57.7% of eFFECTOR Therapeutics shares are held by institutional investors. 6.6% of Calithera Biosciences shares are held by company insiders. Comparatively, 4.7% of eFFECTOR Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Company Net Margins Return on Equity Return on Assets
Calithera BiosciencesN/A N/A N/A
eFFECTOR Therapeutics N/A N/A N/A

Summary

eFFECTOR Therapeutics beats Calithera Biosciences on 4 of the 5 factors compared between the two stocks.

How does Calithera Biosciences compare to Statera Biopharma?

Calithera Biosciences (NASDAQ:CALA) and Statera Biopharma (NASDAQ:STAB) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, valuation, risk, dividends, analyst recommendations, institutional ownership and earnings.

Calithera Biosciences has a beta of -1.32, meaning that its share price is 232% less volatile than the broader market. Comparatively, Statera Biopharma has a beta of -0.06, meaning that its share price is 106% less volatile than the broader market.

In the previous week, Calithera Biosciences' average media sentiment score of 0.00 equaled Statera Biopharma'saverage media sentiment score.

Company Overall Sentiment
Calithera Biosciences Neutral
Statera Biopharma Neutral

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Calithera BiosciencesN/AN/A-$39.65MN/AN/A
Statera BiopharmaN/AN/AN/AN/AN/A

Company Net Margins Return on Equity Return on Assets
Calithera BiosciencesN/A N/A N/A
Statera Biopharma N/A N/A N/A

Summary

Calithera Biosciences and Statera Biopharma tied by winning 1 of the 2 factors compared between the two stocks.

Get Calithera Biosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for CALA and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CALA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CALA vs. The Competition

Export
MetricCalithera BiosciencesPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$1K$936.76M$6.49B$12.31B
Dividend YieldN/A4.84%2.67%5.66%
P/E Ratio0.001.4524.0524.76
Price / SalesN/A129.85542.61168.32
Price / CashN/A20.0627.4837.92
Price / BookN/A7.9810.696.90
Net Income-$39.65M-$4.88M$3.57B$337.45M
7 Day PerformanceN/A5.66%1.56%2.84%
1 Month PerformanceN/A5.57%2.49%4.78%
1 Year PerformanceN/A46.87%26.51%33.08%

Calithera Biosciences Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CALA
Calithera Biosciences
N/A$0.00
flat		N/AN/A$1KN/AN/A60
CARM
Carisma Therapeutics
2.4926 of 5 stars		$0.00
flat		$1.00
+999,900.0%		-98.6%$4K$10.77M0.0020
CMRA
Comera Life Sciences
N/AN/AN/AN/A$3K$1.00MN/A2
EVLO
Evelo Biosciences
N/AN/AN/AN/A$2KN/AN/A120
EFTR
eFFECTOR Therapeutics
N/A$0.00
-66.7%		N/A-33.3%$1KN/AN/A10

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:CALA) was last updated on 6/15/2026 by MarketBeat.com Staff.
From Our Partners
The 1934 playbook
In 1934, a legal government maneuver transferred billions in wealth overnight. Most Americans never saw it com...
American Alternative | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Is SpaceX really worth 1.78 Trillion?
With SpaceX approaching a near-$2 trillion valuation, most investors are focused on the IPO itself - but analy...
InvestPub | Sponsoredtc pixel
Hey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...
After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...
Banyan Hill Publishing | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
SpaceX is chump change compared to Elon’s $20T ‘iPhone’
Early Apple investors saw peak gains as high as 7,537% after the iPhone launched. Now, multiple insider source...
StocksToTrade | Sponsoredtc pixel